PD-L2 is expressed on activated human T cells and regulates their function

Molecular Immunology

Volumn 48, Issue 15-16, 2011, Pages 2214-2219

  Messal, Nassima ^a,b,c   Serriari, Nacer Eddine ^a,b,c   Pastor, Sonia ^a,b,c   Nunès, Jacques A ^a,b,c   Olive, Daniel ^a,b,c  

^a INSERM   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Cell activation; Costimulatory molecules; PD L2; T cells

Indexed keywords

CD4 ANTIGEN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 80051940011     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2011.06.436     Document Type: Article

References (24)

1. Brown J.A., Dorfman D.M., Ma F.R., Sullivan E.L., Munoz O., Wood C.R., Greenfield E.A., Freeman G.J. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. 2003, 170:1257-1266.
2. Butte M.J., Keir M.E., Phamduy T.B., Sharpe A.H., Freeman G.J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007, 27:111-122.
3. Clipstone N.A., Crabtree G.R. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992, 357:695-697.
4. Dong H., Strome S.E., Matteson E.L., Moder K.G., Flies D.B., Zhu G., Tamura H., Driscoll C.L., Chen L. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J. Clin. Invest. 2003, 111:363-370.
5. Dotti G. Blocking PD-1 in cancer immunotherapy. Blood 2009, 114:1457-1458.
6. Fukushima A., Yamaguchi T., Azuma M., Yagita H., Ueno H. Involvement of programmed death-ligand 2 (PD-L2) in the development of experimental allergic conjunctivitis in mice. Br. J. Ophthalmol. 2006, 90:1040-1045.
7. Garcon F., Bismuth G., Isnardon D., Olive D., Nunes J.A. Tec kinase migrates to the T cell-APC interface independently of its pleckstrin homology domain. J. Immunol. 2004, 173:770-775.
8. Ghiotto M., Gauthier L., Serriari N., Pastor S., Truneh A., Nunes J.A., Olive D. PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. Int. Immunol. 2010, 22:651-660.
9. Greenwald R.J., Freeman G.J., Sharpe A.H. The B7 family revisited. Annu. Rev. Immunol. 2005, 23:515-548.
10. Kaku H., Rothstein T.L. Octamer binding protein 2 (Oct2) regulates PD-L2 gene expression in B-1 cells through lineage-specific activity of a unique, intronic promoter. Genes Immun. 2010, 11:55-66.
11. Kuipers H., Muskens F., Willart M., Hijdra D., van Assema F.B., Coyle A.J., Hoogsteden H.C., Lambrecht B.N. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation. Eur. J. Immunol. 2006, 36:2472-2482.
12. Latchman Y., Wood C.R., Chernova T., Chaudhary D., Borde M., Chernova I., Iwai Y., Long A.J., Brown J.A., Nunes R., Greenfield E.A., Bourque K., Boussiotis V.A., Carter L.L., Carreno B.M., Malenkovich N., Nishimura H., Okazaki T., Honjo T., Sharpe A.H., Freeman G.J. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2001, 2:261-268.
13. Nourry C., Grant S.G., Borg J.P. PDZ domain proteins: plug and play!. Sci. STKE 2003, 2003:RE7.
14. Okazaki T., Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 2007, 19:813-824.
15. Paust S., Lu L., McCarty N., Cantor H. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc. Natl. Acad. Sci. U.S.A 2004, 101:10398-10403.
16. Riley J.L. PD-1 signaling in primary T cells. Immunol. Rev. 2009, 229:114-125.
17. Riley J.L., Schlienger K., Blair P.J., Carreno B., Craighead N., Kim D., Carroll R.G., June C.H. Modulation of susceptibility to HIV-1 infection by the cytotoxic T lymphocyte antigen 4 costimulatory molecule. J. Exp. Med. 2000, 191:1987-1997.
18. Said E.A., Dupuy F.P., Trautmann L., Zhang Y., Shi Y., El-Far M., Hill B.J., Noto A., Ancuta P., Peretz Y., Fonseca S.G., Van Grevenynghe J., Boulassel M.R., Bruneau J., Shoukry N.H., Routy J.P., Douek D.C., Haddad E.K., Sekaly R.P. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat. Med. 2010, 16:452-459.
19. Sansom D.M., Hall N.D. B7/BB1, the ligand for CD28, is expressed on repeatedly activated human T cells in vitro. Eur. J. Immunol. 1993, 23:295-298.
20. Serriari N.E., Gondois-Rey F., Guillaume Y., Remmerswaal E.B., Pastor S., Messal N., Truneh A., Hirsch I., van Lier R.A., Olive D. B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function. J. Immunol. 2010, 185:3140-3148.
21. Taylor P.A., Lees C.J., Fournier S., Allison J.P., Sharpe A.H., Blazar B.R. B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]. J. Immunol. 2004, 172:34-39.
22. Van Keulen V.P., Ciric B., Radhakrishnan S., Heckman K.L., Mitsunaga Y., Iijima K., Kita H., Rodriguez M., Pease L.R. Immunomodulation using the recombinant monoclonal human B7-DC cross-linking antibody rHIgM12. Clin. Exp. Immunol. 2006, 143:314-321.
23. Yamazaki T., Akiba H., Iwai H., Matsuda H., Aoki M., Tanno Y., Shin T., Tsuchiya H., Pardoll D.M., Okumura K., Azuma M., Yagita H. Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 2002, 169:5538-5545.
24. Zhu B., Guleria I., Khosroshahi A., Chitnis T., Imitola J., Azuma M., Yagita H., Sayegh M.H., Khoury S.J. Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. J. Immunol. 2006, 176:3480-3489.